S&P/ASX 200 morning report – AMP, RMD & US big tech shares in focus
Drew Meredith, CFP
November 2, 2020
The S&P/ASX 200 (ASX: XJO) is expected to trade higher
ResMed Inc (ASX: RMD) is a United States based business that develops and manufactures medical devices to help people with sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed, which is short for Respiratory Medicine, was founded in 1989 by Dr Peter Farrell and now helps customers & patients in over 120 countries.
The S&P/ASX 200 (ASX: XJO) is expected to trade higher
The S&P/ASX 200 (INDEXASX: XJO) is expected to edge lower
The ResMed Inc (ASX:RMD) profit jumped 40% in its FY20
The Avita Therapeutics Inc (ASX: AVH) share price was trading
The All Ordinaries (ASX: XAO) is 3.8% in the red
The ResMed (ASX:RMD) share price is up around 5% despite
The Cochlear Limited (ASX: COH) share price was trading 19.25%
The All Ordinaries (ASX: XAO) was trading 1.9% higher today
The ResMed (ASX:RMD) share price was trading 2.63% higher today
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
